BioSpace News Archive

Dyne Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 19,722,500 shares of its common stock at a public offering price of $17.50 per share, which includes 2,572,500 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering.

CVRx, Inc. (NASDAQ: CVRX) (“CVRx”) today announced that it plans to release fourth quarter 2023 financial and operating results after market close on Thursday, January 25th, 2024.

Indapta Therapeutics, Inc. today announced that the company has initiated treatment of the first patients in its Phase 1 trial in multiple myeloma and Non-Hodgkin’s lymphoma.

Mustang Bio, Inc. today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference.

Nexalin Technology, Inc. today unveiled its Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device designed to treat a variety of mental health conditions, including Major Depressive Disorder (MDD).

DarioHealth Corp., a leader in the global digital health market, announced a new contract to provide its cardiometabolic solution to a regional union, expected to begin in the first quarter of 2024.

CB Scientific. Inc. today is providing its shareholders with a 2023 year-end review from Charles Martin, Chief Executive Officer.

Resverlogix Corp. (TSX: RVX) (“Resverlogix”, “the Company”) today announced publication of an article, entitled, “The BET inhibitor apabetalone decreases

USAntibiotics today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.

Autonomix Medical, Inc. announced the completion of its engineering development team formation and provided an engineering update.